Filing Details
- Accession Number:
- 0001209191-21-025119
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-05 16:10:27
- Reporting Period:
- 2021-04-01
- Accepted Time:
- 2021-04-05 16:10:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1437435 | Marc Tessier-Lavigne | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-04-01 | 14,223 | $55.61 | 2,628,073 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-01 | 29,593 | $56.91 | 2,598,480 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-01 | 6,184 | $57.60 | 2,592,296 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.22 to $56.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 3,253 restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.23 to $57.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.23 to $58.095 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
